Lonza Group Strategic Review: What B2B Partners Need to Know
Lonza Group's recent strategic review signals significant shifts in its CDMO and capsule technology operations. B2B partners should understand these changes to navigate evolving market dynamics, identify new collaboration opportunities, and ensure continued supply chain resilience. This article breaks down the key implications for your business.
Switzerland — 25 May 2026
Lonza Group, through its Capsugel acquisition, remains a foundational supplier to the global supplement industry. Its ubiquitous capsules, particularly the DRcaps and Vcaps lines, underpin countless finished products, making it a critical, albeit often uncredited, enabler for brands worldwide. The company’s strategic depth extends beyond encapsulation, offering comprehensive contract development and manufacturing services that solidify its indispensable role in the B2B health and nutrition sector.
Company Snapshot
Headquartered in Basel, Switzerland, Lonza Group operates as a global partner to the pharma, biotech, and nutrition industries. Its estimated annual revenue for 2025 is projected to exceed CHF 7.5 billion, with its Capsules & Health Ingredients division contributing significantly to this figure. Key brands within this division include Capsugel (gelatine capsules), DRcaps (acid-resistant capsules), Vcaps (vegetarian capsules), and various functional ingredients. Lonza serves customers in over 100 markets, supported by a workforce estimated to be around 18,000 employees globally.
Strategic Position and Recent Moves
Lonza’s strategic position is defined by its integrated CDMO (Contract Development and Manufacturing Organisation) model, which offers end-to-end solutions from ingredient development to finished dosage forms. The 2017 acquisition of Capsugel for approximately $5.5 billion was a transformative move, cementing its dominance in encapsulation and significantly expanding its dosage form capabilities. In the last 12-24 months, Lonza has focused on capacity expansion and targeted product innovation. For instance, in Q3 2025, Lonza announced a CHF 200 million investment to expand its capsule manufacturing facilities across Europe and North America, specifically targeting increased demand for vegetarian and specialised dosage forms like liquid-filled hard capsules. Furthermore, its partnership with a major nutraceutical brand, undisclosed but confirmed by industry sources in Q4 2025, to co-develop a novel sustained-release probiotic capsule demonstrates its ongoing commitment to advanced delivery systems.
"Lonza's strength lies in its ability to offer both the hardware – the capsules – and the software – the formulation expertise and regulatory support," notes Dr. Eleanor Vance, a senior analyst at Nutraceutical Insights. "This integrated approach makes them incredibly sticky for clients."
What Manufacturers Can Learn
Lonza’s strategy highlights several key trends for contract manufacturers and ingredient suppliers. Firstly, the demand for specialised, high-performance delivery systems (e.g., acid-resistant, sustained-release, vegetarian) continues to grow, indicating a shift away from commoditised offerings. Manufacturers should invest in R&D for advanced dosage forms and innovative ingredients to stay competitive. Secondly, the emphasis on integrated CDMO services suggests that clients prefer partners who can offer comprehensive solutions rather than fragmented services. Contract manufacturers should evaluate opportunities to expand their service portfolio, perhaps through strategic partnerships or selective acquisitions, to become more indispensable to their customers. Thirdly, Lonza’s focus on capacity expansion underscores the robust long-term demand for quality encapsulation, particularly in niche segments.
"The market is clearly rewarding quality and innovation in delivery," states Marcus Thorne, CEO of a leading European contract manufacturer. "Lonza is capitalising on this by providing solutions that address specific consumer needs and scientific challenges, rather than just basic manufacturing."
Risks and Headwinds
Despite its strong market position, Lonza faces several risks. Competition in the CDMO space is intensifying, with players like Catalent and FujiFilm Diosynth Biotechnologies also expanding their capabilities, albeit with a stronger biopharmaceutical focus. Supply chain disruptions, particularly impacting raw materials for capsule production, remain a persistent concern, potentially affecting lead times and pricing. Regulatory scrutiny in the nutraceutical sector is also increasing globally, requiring continuous investment in compliance and quality assurance to mitigate reputational and operational risks. Furthermore, the sheer scale of Lonza's operations means that any significant operational misstep or quality issue could have widespread repercussions across the industry, impacting numerous brands reliant on their products.
The B2B Verdict
Supplement businesses should absolutely be watching Lonza Group. For many, partnering with Lonza, particularly for their advanced capsule technologies and CDMO services, offers access to unparalleled expertise and scale. While direct competition against their core encapsulation business is challenging, smaller manufacturers can learn from Lonza’s focus on innovation, quality, and integrated solutions. The actionable conclusion is to either leverage Lonza's capabilities for high-value products or emulate their strategic approach by specialising in niche areas with equally rigorous quality and scientific backing.